Home›Fostamatinib

Fostamatinib

Also known as: Tavalisse

Route: Oral

9 interactions on record

Fostamatinib has 9 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rosuvastatin, Rosuvastatin Calcium, Atazanavir. Patients taking Fostamatinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 9
Major: 2
Moderate: 6

Major (2)

Fostamatinib + Rosuvastatin— Fostamatinib increased rosuvastatin exposure more than 2.0-fold, increasing the risk of myopathy and rhabdomyolysis. Do …
Fostamatinib + Rosuvastatin Calcium— Fostamatinib increases rosuvastatin exposure more than 2.0-fold, increasing risk of myopathy and rhabdomyolysis. Do not …

Moderate (6)

Fostamatinib + Atazanavir— Kinase inhibitors: fostamatinib ↑ R406 (active metabolite of fostamatinib) When coadministering fostamatinib with REYATA…
Fostamatinib + Atazanavir Sulfate— Kinase inhibitors: fostamatinib ↑ R406 (active metabolite of fostamatinib) When coadministering fostamatinib with atazan…
Fostamatinib + Digoxin— Fostamatinib may increase concentrations of digoxin (P-glycoprotein substrate). Monitor for toxicities that may require …
Fostamatinib + Lopinavir And Ritonavir— Kinase Inhibitors: fostamatinib (also see anticancer agents above) ↑ fostamatinib metabolite R406 Monitor for toxicities…
Fostamatinib + Ritonavir— Kinase Inhibitors: fostamatinib (also see anticancer agents above ) ↑ fostamatinib metabolite R406 Monitor for toxicitie…
Fostamatinib + Ritonavir 100 Mg— Kinase Inhibitors: fostamatinib (also see anticancer agents above) ↑ fostamatinib metabolite R406 Monitor for toxicities…

Fostamatinib + Rosuvastatin⚠️Major

Fostamatinib increased rosuvastatin exposure more than 2.0-fold, increasing the risk of myopathy and rhabdomyolysis. Do not exceed rosuvastatin 20 mg once daily.

Fostamatinib + Rosuvastatin Calcium⚠️Major

Fostamatinib increases rosuvastatin exposure more than 2.0-fold, increasing risk of myopathy and rhabdomyolysis. Do not exceed 20 mg rosuvastatin once daily.

Fostamatinib + Atazanavir🟡Moderate

Kinase inhibitors: fostamatinib ↑ R406 (active metabolite of fostamatinib) When coadministering fostamatinib with REYATAZ (with or without ritonavir), monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.

Fostamatinib + Atazanavir Sulfate🟡Moderate

Kinase inhibitors: fostamatinib ↑ R406 (active metabolite of fostamatinib) When coadministering fostamatinib with atazanavir (with or without ritonavir), monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.

Fostamatinib + Digoxin🟡Moderate

Fostamatinib may increase concentrations of digoxin (P-glycoprotein substrate). Monitor for toxicities that may require dosage reduction.

Fostamatinib + Lopinavir And Ritonavir🟡Moderate

Kinase Inhibitors: fostamatinib (also see anticancer agents above) ↑ fostamatinib metabolite R406 Monitor for toxicities of R406 such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.

Fostamatinib + Ritonavir🟡Moderate

Kinase Inhibitors: fostamatinib (also see anticancer agents above ) ↑ fostamatinib metabolite R406 Monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.

Fostamatinib + Ritonavir 100 Mg🟡Moderate

Kinase Inhibitors: fostamatinib (also see anticancer agents above) ↑ fostamatinib metabolite R406 Monitor for toxicities of R406 exposure resulting in dose-related adverse events such as hepatotoxicity and neutropenia. Fostamatinib dose reduction may be required.

Fostamatinib + Atazanavir And Cobicistatℹ️Unknown

Kinase inhibitors: fostamatinib ↑ R406 active metabolite of fostamatinib Coadministration with fostamatinib may increase the plasma concentration of R406, the active metabolite of fostamatinib. Fostamatinib dose reduction may be required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.